4-chloro-3-(oxazolo[4,5-b]pyridin-2-yl)-aniline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-chloro-3-(oxazolo[4,5-b]pyridin-2-yl)-aniline
• 英文别名: 4-chloro-3-(oxazolo[4,5-b]pyridin-2-yl)benzenamine；4-chloro-3-oxazolo[4,5-b]pyridin-2-yl-phenylamine；4-Cloro-3-oxazolo[4,5-b]pyridin-2-yl-phenylamine；4-Chloro-3-([1,3]oxazolo[4,5-b]pyridin-2-yl)aniline
• 化学式: C₁₂H₈ClN₃O
• mdl: MFCD02258048
• 分子量: 245.668
• InChiKey: FBJLATKOADLRTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-3-(oxazolo[4,5-b]pyridin-2-yl)-aniline 在 4-二甲氨基吡啶 、 caesium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-chloro-3-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-N-methylbenzamide
  参考文献：
  名称：

  3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis

  摘要：

  A whole organism high-throughput screen of approximately 87,000 compounds against Trypanosoma brucei brucei led to the recent discovery of several novel compound classes with low micromolar activity against this organism and without appreciable cytotoxicity to mammalian cells. Herein we report a structure activity relationship (SAR) investigation around one of these hit classes, the 3-(oxazolo[4,5-b] pyridin-2-yl)anilides. Sharp SAR is revealed, with our most active compound (5) exhibiting an IC50 of 91 nM against the human pathogenic strain T.b. rhodesiense and being more than 700 times less toxic towards the L6 mammalian cell line. Physicochemical properties are attractive for many compounds in this series. For the most potent representatives, we show that solubility and metabolic stability are key parameters to target during future optimisation.[GRAPHICS](C) 2013 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2013.05.007
• 作为产物：
  描述：

  2-氨基-3-羟基吡啶 在 tin(II) chloride dihdyrate 作用下， 以 乙酸乙酯 为溶剂， 反应 5.0h， 生成 4-chloro-3-(oxazolo[4,5-b]pyridin-2-yl)-aniline
  参考文献：
  名称：

  Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis

  摘要：

  A phenotypic screen of a compound library for antiparasitic activity on Trypanosoma brucei, the causative agent of human African trypanosomiasis, led to the identification of substituted 2-(3-aminophenyl)oxazolopyridines as a starting point for hit-to-lead medicinal chemistry. A total of 110 analogues were prepared, which led to the identification of 64, a substituted 2-(3-aminophenyl)imidazopyridine. This compound showed antiparasitic activity in vitro with an EC50 of 2 nM and displayed reasonable druglike properties when tested in a number of in vitro assays. The compound was orally bioavailable and displayed good plasma and brain exposure in mice. Compound 64 cured mice infected with Trypanosorna brucei when dosed orally down to 2.5 mg/kg. Given its potent antiparasitic properties and its ease of synthesis, compound 64 represents a new lead for the development of drugs to treat human African trypanosomiasis.

  DOI：

  10.1021/jm401178t

文献信息

• Benzoxazole LPAAT-B inhibitors and uses thereof
  申请人：CELL THERAPEUTICS, INC.

  公开号：US20020107269A1

  公开（公告）日：2002-08-08

  The invention relates to benzoxazoles and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening for LPAAT-&bgr; activity.

  该发明涉及苯并噁唑及其用途，用于抑制溶磷脂酸酰基转移酶β（LPAAT-β）活性。该发明还涉及使用所述苯并噁唑治疗癌症的方法。该发明还涉及筛选LPAAT-β活性的方法。
• Antitrypanosomal Chloronitrobenzamides
  作者：Angela K. Carrillo、Tara Man Kadayat、Jong Yeon Hwang、Yizhe Chen、Fangyi Zhu、Gloria Holbrook、Kirsten Gillingwater、Michele C. Connelly、Lei Yang、Marcel Kaiser、R. Kiplin Guy

  DOI：10.1021/acs.jmedchem.3c01680

  日期：2024.3.14

  disease caused by Trypanosoma brucei gambiense (Tbg) or Trypanosoma brucei rhodesiense (Tbr), remains a significant public health concern with over 55 million people at risk of infection. Current treatments for HAT face the challenges of poor efficacy, drug resistance, and toxicity. This study presents the synthesis and evaluation of chloronitrobenzamides (CNBs) against Trypanosoma species, identifying

  非洲人类锥虫病 (HAT) 是一种被忽视的热带疾病，由布氏冈比亚锥虫( Tbg ) 或罗得西亚布氏锥虫( Tbr ) 引起，仍然是一个重大的公共卫生问题，超过 5500 万人面临感染风险。目前HAT的治疗面临着疗效差、耐药性和毒性的挑战。本研究介绍了针对锥虫物种的氯硝基苯甲酰胺 (CNB) 的合成和评估，鉴定了先前报道的化合物52作为一种有效的、选择性的口服生物可利用的抗锥虫药物。 52在体内具有良好的耐受性，并表现出良好的口服药代动力学，在 24 小时内维持超过细胞 EC 50 的血浆浓度，并且在单次口服给药（50 mg/kg）后在啮齿类动物中达到超过 7 μM 的峰值脑浓度。 52治疗显着延长了感染刚果锥虫和罗得西亚锥虫的小鼠的寿命。这些结果表明， 52是一种强效抗锥虫先导药物，具有开发治疗人类和动物非洲锥虫病的潜力。
• [EN] BENZOXAZOLE LPAAT- beta INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS BENZOXAZOLES DE LPAAT- DOLLAR G(B) ET UTILISATIONS ASSOCIEES
  申请人：BONHAM LYNN

  公开号：WO2002036580A2

  公开（公告）日：2002-05-10

  The invention relates to benzoxazoles of the following Formula, wherein the variables are defined in the claims and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening to LPAAT-β activitiy.
• [EN] BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS BENZOXAZOLES DE LPAAT- DOLLAR G(B) ET UTILISATIONS ASSOCIEES
  申请人：——

  公开号：WO2002036580A9

  公开（公告）日：2003-02-13

  [EN] The invention relates to benzoxazoles of the following Formula, wherein the variables are defined in the claims and the use thereof to inhibit lysophosphatidic acid acyltransferase beta (LPAAT- beta ) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening to LPAAT- beta activitiy.
  [FR] L'invention concerne des benzoxazoles et l'utilisation de ceux-ci dans l'inhibition de l'activité de l'acide lysophosphatidique de l'acyltransférase beta (LPAAT- beta ). L'invention concerne en outre des méthodes de traitement de cancer mettant en oeuvre ces benzoxazoles. L'invention concerne enfin des méthodes de criblage de l'activité de LPAAT- beta .
• Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis
  作者：Hari Babu Tatipaka、J. Robert Gillespie、Arnab K. Chatterjee、Neil R. Norcross、Matthew A. Hulverson、Ranae M. Ranade、Pendem Nagendar、Sharon A. Creason、Joshua McQueen、Nicole A. Duster、Advait Nagle、Frantisek Supek、Valentina Molteni、Tanja Wenzler、Reto Brun、Richard Glynne、Frederick S. Buckner、Michael H. Gelb

  DOI：10.1021/jm401178t

  日期：2014.2.13

  A phenotypic screen of a compound library for antiparasitic activity on Trypanosoma brucei, the causative agent of human African trypanosomiasis, led to the identification of substituted 2-(3-aminophenyl)oxazolopyridines as a starting point for hit-to-lead medicinal chemistry. A total of 110 analogues were prepared, which led to the identification of 64, a substituted 2-(3-aminophenyl)imidazopyridine. This compound showed antiparasitic activity in vitro with an EC50 of 2 nM and displayed reasonable druglike properties when tested in a number of in vitro assays. The compound was orally bioavailable and displayed good plasma and brain exposure in mice. Compound 64 cured mice infected with Trypanosorna brucei when dosed orally down to 2.5 mg/kg. Given its potent antiparasitic properties and its ease of synthesis, compound 64 represents a new lead for the development of drugs to treat human African trypanosomiasis.